Cardiogen

guinea pig

Also seen as: AEDR, Ala-Glu-Asp-Arg

The Dose Guy’s verdict

Sep 1, 2026
2 sources

Skip it. Cell dishes and rat tissue, no human trial, no pharmacokinetics, no safety data. The myocardial cell work is mildly interesting, and a rat tumor model gave a reassuring direction, but none of this tells you what cardiogen does in a living person’s heart. If cardiac health is the goal, the answer is training, sleep, and managing the numbers your doctor already tracks, not a tetrapeptide with no human data.

Would I take it?Not without a human trial.

What it is

A four-amino-acid synthetic bioregulator from the Khavinson program, designed to support cardiac tissue. The family logic is that short peptides modeled on specific organs can signal repair in those tissues. Cardiogen is the heart version, with a small published base of rat explant and cell-culture work.

Among the Khavinson bioregulators, epitalon has the most published evidence and the closest thing to a human data point. Cardiogen is well behind it.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Cell-culture and rat data only. No human trial, no pharmacokinetics, no systematic review:

Cardiogen produced a strong stimulatory effect on cell proliferation in myocard tissue from both young and old rats, with decreased p53 expression on immunohistochemistry.Adv Gerontol 2009 · rat myocardial explants

In senescent rats with transplanted M-1 sarcoma, cardiogen injections produced dose-dependent inhibition of tumor growth, with higher tumor-cell apoptosis in every treated group than in controls.Bull Exp Biol Med 2009 · rat sarcoma

No human efficacy trial, safety study, or pharmacokinetic data exists for cardiogen.as of Aug 2026

Realistic protocols

No published study supports a human dose, route, or duration for cardiogen. The community borrows the Khavinson bioregulator course: short subcutaneous runs of 10 to 20 days, a few times a year. That schedule is tradition from the Khavinson program, not a protocol anyone has validated. For a peptide aimed at the heart with zero human data, keep any experiment short and respect the gap.

Side effects

No human safety data exists:

unknownZero human safety or tolerability data. For a peptide aimed at cardiac tissue, that gap is especially uncomfortable. You do not experiment casually with your heart.

anecdotalPeople running bioregulator stacks almost never single out cardiogen. No specific effect attributed to it in community reports, positive or negative.

Where to buy

No live listings from tracked vendors right now.